Volumen: 16 # Number : 1
Publication Date : Enero - Abril Year: 2012
Authors: Lucía A. Zoppegno, María M Moirano, Maria L Negro,
Susana H. Bunzel, Alicia M Gelemur
Abstract: Rituximab is now part of the standard treatment of B NHL. This therapeutic modality adds new side effects on the immune system.
We analyzed the incidence of hypogammaglobulinemia and its association with infectious episodes in the absence of neutropenia in patients with B NHL treated with Rituximab. The study included 68 patients who received Rituximab with weekly schedule or every 21/28 days in combination with chemotherapy. Patients treated with fludarabine were excluded.
Immunoglobulins were determined at regular intervals of time. We analyzed the infectious episodes associated with hypogammaglobulinemia.
The incidence of hypogammaglobulinemia was 63.64% in the weekly scheme, 44.85% and 75% in the 21 and 28 day schedule respectively. Thirteen patients (19.1%) presented infectious events. Eleven of them had hypogammaglobulinemia.
There were no fatal events.
Rituximab was associated with a high incidence of hypogammaglobulinemia, which did not result in severe infectious episodes or fatal events.
Keywords: lymphoma, Rituximab, hypogammaglobulinemia
Key words:
Pages : 3-7
|
